Pricing Log in Create free account

Cardiff Oncology, Inc. (CRDF) vs Pelthos Therapeutics Inc. (PTHS)

Cardiff Oncology, Inc. and Pelthos Therapeutics Inc. are both Biotechnology companies. Cardiff Oncology, Inc. and Pelthos Therapeutics Inc. are of similar size ($77.6M and $75.5M). Pelthos Therapeutics Inc. has the higher net margin (−199.5% vs −7,889.0%) and the lower return on invested capital (−82.3% vs 0.00%). Across the 15 metrics below, Pelthos Therapeutics Inc. leads on 9 and Cardiff Oncology, Inc. on 6.

Valuation

Metric CRDF PTHS Biotechnology median
P/E n/m n/m 8.50
P/S 122.52 1.65 9.71
P/B 2.35 n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m n/m 0.64
EV/Sales 57.34 2.75 9.21
Earnings yield (65.93%) (142.54%) (33.15%)
Free cash flow yield (65.78%) (59.72%) (25.50%)

Profitability

Metric CRDF PTHS Biotechnology median
Gross margin 100.00% 78.59% 65.16%
Operating margin (8,320.08%) (133.42%) 0.00%
Net margin (7,888.98%) (199.50%) 0.00%
Free cash flow margin (8,059.45%) (98.37%) 0.00%
Return on equity (94.14%) 2,161.07% (56.36%)
Return on assets (70.89%) (125.04%) (48.04%)
Return on invested capital 0.00% (82.34%) 0.00%

Growth

Metric CRDF PTHS Biotechnology median
Revenue growth (TTM) (6.79%) — 6.02%
EPS growth (last fiscal year) 27.37% (61.12%) 30.26%
Revenue growth, 5-year CAGR 10.13% — 9.41%
Net income growth, 5-year CAGR 0.00% — 0.00%

Health

Metric CRDF PTHS Biotechnology median
Debt to equity 0.00 (46.58) 0.00
Current ratio 3.30 1.98 4.72
Net debt to EBITDA 1.18 (0.45) 0.96

Dividend

Metric CRDF PTHS Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric CRDF PTHS Biotechnology median
Market cap 75.54m 77.57m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack